BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 12803319)

  • 1. Immunological effects of thalidomide and its chemical and functional analogs.
    Dredge K; Marriott JB; Dalgleish AG
    Crit Rev Immunol; 2002; 22(5-6):425-37. PubMed ID: 12803319
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thalidomide derived immunomodulatory drugs (IMiDs) as potential therapeutic agents.
    Marriott JB; Dredge K; Dalgleish AG
    Curr Drug Targets Immune Endocr Metabol Disord; 2003 Sep; 3(3):181-6. PubMed ID: 12871024
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thalidomide: mechanisms of action.
    Paravar T; Lee DJ
    Int Rev Immunol; 2008; 27(3):111-35. PubMed ID: 18437602
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thalidomide analogs as emerging anti-cancer drugs.
    Dredge K; Dalgleish AG; Marriott JB
    Anticancer Drugs; 2003 Jun; 14(5):331-5. PubMed ID: 12782937
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selective cytokine inhibitory drugs with enhanced antiangiogenic activity control tumor growth through vascular inhibition.
    Gee MS; Makonnen S; al-Kofahi K; Roysam B; Payvandi F; Man HW; Muller GW; Lee WM
    Cancer Res; 2003 Dec; 63(23):8073-8. PubMed ID: 14678955
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunomodulatory effects of thalidomide analogs on LPS-induced plasma and hepatic cytokines in the rat.
    Fernández-Martínez E; Morales-Ríos MS; Pérez-Alvarez V; Muriel P
    Biochem Pharmacol; 2004 Oct; 68(7):1321-9. PubMed ID: 15345321
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thalidomide and lenalidomide in the treatment of multiple myeloma.
    Kumar S; Rajkumar SV
    Eur J Cancer; 2006 Jul; 42(11):1612-22. PubMed ID: 16750621
    [TBL] [Abstract][Full Text] [Related]  

  • 8. IMiDs: a novel class of immunomodulators.
    Knight R
    Semin Oncol; 2005 Aug; 32(4 Suppl 5):S24-30. PubMed ID: 16085014
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lenalidomide and thalidomide: mechanisms of action--similarities and differences.
    Anderson KC
    Semin Hematol; 2005 Oct; 42(4 Suppl 4):S3-8. PubMed ID: 16344099
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thalidomide for the treatment of multiple myeloma.
    Hattori Y; Iguchi T
    Congenit Anom (Kyoto); 2004 Sep; 44(3):125-36. PubMed ID: 15327481
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic use of immunomodulatory drugs in the treatment of multiple myeloma.
    Raje N; Hideshima T; Anderson KC
    Expert Rev Anticancer Ther; 2006 Sep; 6(9):1239-47. PubMed ID: 17020458
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The thalidomide saga.
    Melchert M; List A
    Int J Biochem Cell Biol; 2007; 39(7-8):1489-99. PubMed ID: 17369076
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thalidomide: a novel template for anticancer drugs.
    Stirling D
    Semin Oncol; 2001 Dec; 28(6):602-6. PubMed ID: 11740817
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Angiogenesis inhibitors derived from thalidomide.
    Noguchi T; Fujimoto H; Sano H; Miyajima A; Miyachi H; Hashimoto Y
    Bioorg Med Chem Lett; 2005 Dec; 15(24):5509-13. PubMed ID: 16183272
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunotherapeutic and antitumour potential of thalidomide analogues.
    Marriott JB; Muller G; Stirling D; Dalgleish AG
    Expert Opin Biol Ther; 2001 Jul; 1(4):675-82. PubMed ID: 11727503
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adverse effects of thalidomide administration in patients with neoplastic diseases.
    Dimopoulos MA; Eleutherakis-Papaiakovou V
    Am J Med; 2004 Oct; 117(7):508-15. PubMed ID: 15464708
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antitumor effects of thalidomide analogs in human prostate cancer xenografts implanted in immunodeficient mice.
    Ng SS; MacPherson GR; Gütschow M; Eger K; Figg WD
    Clin Cancer Res; 2004 Jun; 10(12 Pt 1):4192-7. PubMed ID: 15217957
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Thalidomid: current role in the treatment of non-plasma cell malignancies.
    Kumar S; Witzig TE; Rajkumar SV
    J Clin Oncol; 2004 Jun; 22(12):2477-88. PubMed ID: 15197211
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recent advances of IMiDs in cancer therapy.
    Li S; Gill N; Lentzsch S
    Curr Opin Oncol; 2010 Nov; 22(6):579-85. PubMed ID: 20689431
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.